Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

2'-cyano-2'-deoxyarabinofuranosylcytosine

Known as: 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine, 2'-cyano-2'deoxy-1-beta-D-arabinofuranosylcytosine, CNDAC 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Cytarabine

Narrower (1)

Nucleoside Analog DFP-10917
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors
2'-C-cyano-2'-deoxy-1-β-d-arabino-pentofuranosylcytosine (CNDAC) is the active metabolite of the anticancer drug, sapacitabine… Expand
Is this relevant?
2008
2008
Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2′-C-cyano-2′-deoxy-1-β-d-arabino…
2′-C-Cyano-2′-deoxy-1-β-d-arabino-pentofuranosylcytosine (CNDAC), the prodrug (sapacitabine) of which is in clinical trials, has… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells
This study assessed the antiproliferative activity of sapacitabine (CYC682, CS-682) in a panel of 10 human cancer cell lines with… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies
SummaryThe development of nucleoside analogues has had a major impact on cancer therapy. CS-682 is a novel, orally administered… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2005
2005
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) is a nucleoside analogue with a novel mechanism of action… Expand
Is this relevant?
2004
2004
Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase.
Because membrane type-1 matrix metalloproteinase (MT1-MMP) is expressed specifically on the angiogenic endothelium as well as… Expand
Is this relevant?
Review
2004
Review
2004
Antitumor activity of sugar-modified cytosine nucleosides.
Nucleoside analogues which show antimetabolic activity in cells have been successfully used in the treatment of various tumors… Expand
  • table I
  • table II
  • table III
  • table IV
  • figure 2
Is this relevant?
2002
2002
Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels.
We previously reported that liposomalized 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino… Expand
Is this relevant?
2001
2001
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
The mechanism of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) action was investigated in human… Expand
Is this relevant?
1999
1999
Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
We have studied the antitumor activity and the novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-Ccyano-2-deoxy-beta-D… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE